Fractyl Health (NASDAQ:GUTS) Issues Quarterly Earnings Results

Fractyl Health (NASDAQ:GUTS - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.08), Zacks reports.

Fractyl Health Trading Down 1.3 %

NASDAQ GUTS traded down $0.02 on Thursday, hitting $1.57. 221,134 shares of the stock were exchanged, compared to its average volume of 306,917. Fractyl Health has a 52-week low of $1.37 and a 52-week high of $9.36. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The company has a market capitalization of $75.52 million and a price-to-earnings ratio of -0.13. The company's 50-day moving average price is $1.75 and its two-hundred day moving average price is $2.27.

Analysts Set New Price Targets

Separately, Morgan Stanley decreased their price target on shares of Fractyl Health from $18.00 to $10.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd.

Insiders Place Their Bets

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the transaction, the insider now owns 153,544 shares in the company, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Remove Ads

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.